Stocktoria
NRX Pharmaceuticals, Inc. NRXP
NRX Pharmaceuticals, Inc. (NRXP) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $1.4M at a -1980.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| IGC | IGC Pharma, Inc. | 3/9 | — | — | — |
| VTGN | Vistagen Therapeutics, Inc. | 2/9 | — | — | — |
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
About NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
FAQ
Is NRXP financially healthy?
NRX Pharmaceuticals, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does NRXP pay a dividend?
No, NRX Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is NRXP?
In FY2025, NRX Pharmaceuticals, Inc. had a net margin of -1980.8%.
What is the analyst price target for NRXP?
The average Wall-Street price target for NRX Pharmaceuticals, Inc. is $42.00, about 1150.0% above the recent price, from 4 analysts (consensus: strong buy).
Is NRXP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NRX Pharmaceuticals, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.